Pfizer – Cardiac Transthyretin Amyloid (ATTR) Fellowship – Call for Proposals

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire within unit

Memorial Deadline: Wednesday 21st, December 2022

External Deadline: Thursday 5th, January 2023


The International Society of Amyloidosis (ISA) and Pfizer are collaborating to offer a new competitive grant opportunity focused on supporting fellowships in Cardiac Transthyretin Amyloid (ATTR).

The mission of the International Society of Amyloidosis (ISA) is to promote research, education, clinical studies (including diagnosis and treatment), conferences and symposia on all aspects of amyloidosis worldwide.

The mission of Pfizer Global Medical Grants is to accelerate the translation of science into quality patient care through independent grants, partnerships, and collaborations. Pfizer Global Medical Grants supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.


Date RFP Issued: December 2, 2022

Geographic Scope: Global

Clinical Area: Cardiac Transthyretin Amyloid (ATTR)

Link to full RFP: Cardiac Transthyretin Amyloid (ATTR) Fellowship

Application Due Date: January 5, 2023

Specific Area of Interest: The goal of this program is to train physicians to recognize and diagnose cardiac ATTR amyloidosis. Fellowships will be structured to support experienced amyloidosis centers in hosting fellows from regions around the globe where a high level of expertise in cardiac amyloidosis is lacking. Fellows are expected to return to their home institutions to provide expertise and mentoring on cardiac ATTR amyloidosis in their regions.

More details can be found here.

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: December 6, 2022